Total COVID-19 cases in India jump to 959 on fourth day of nationwide lockdown | We all are one in this battle against COVID-19: PM Modi | RBI took giant steps to safeguard economy from COVID-19 impact: PM Modi | Government taking care of Bengal workers stuck in Maharashtra: Aaditya Thackeray responds to Mamata's request | First step in right direction: Rahul Gandhi praises Centre's mega package amid COVID-19 crisis |

Dr Reddy's acquires rights to an investigational anti-cancer agent

India blooms News Service | 31 Mar 2016, 07:47 pm
Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.
Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.
 
In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.  

Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."

Dr Reddy's acquires rights to an investigational anti-cancer agent

India blooms News Service
Comments ()

Post your comment:

Web Analytics